auranofin

Contraindicated in:

Hypersensitivity;
Previous gold toxicity (e.g., anaphylaxis, necrotizing enterocolitis, pulmonary fibrosis, exfoliative dermatitis, bone marrow aplasia, hematologic disorders);
OB: Preganancy;
Lactation: Lactation.

Use Cautiously in:

History of blood dyscrasias;
Rash;
Severe renal impairment;
Severe hepatic impairment;
Inflammatory bowel disease;
Pedi: Safety and effectiveness not established in children.

Adv. Reactions/Side Effects ⬆ ⬇

Derm: dermatitis, pruritus, rash, alopecia, photosensitivity reactions, urticaria

EENT: conjunctivitis, corneal gold deposition

GI: abdominal pain, cramping, diarrhea, stomatitis, ↑liver enzymes, flatulence, anorexia, difficulty swallowing, dyspepsia, GI BLEEDING, gingivitis, glossitis, metallic taste, nausea, vomiting

GU: hematuria, proteinuria

Hemat: AGRANULOCYTOSIS, anemia, APLASTIC ANEMIA, eosinophilia, , leukopenia, thrombocytopenia

Neuro: peripheral neuropathy

Resp: bronchitis, pneumonitis, pulmonary fibrosis

Misc: ANGIOEDEMA, HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS)

Interactions ⬆ ⬇

Drug-drug:

Bone marrow toxicity may be additive with other myelosuppressive agents (antineoplastics, radiation therapy, azathioprine) or high doses of corticosteroids.
Penicillamine may ↑ risk of adverse hematologic or renal reactions.
May ↑ levels and risk of toxicity of phenytoin.

Availability ⬆ ⬇

Route/Dosage ⬆ ⬇

PO (Adults ): 6 mg/day in 1–2 doses; may ↑ to 9 mg/day in 3 divided doses if no improvement after 6 mo.

US Brand Names ⬆ ⬇

Action ⬆ ⬇

Inhibits inflammatory process.
Modifies immune response (immunomodulating properties).

Therapeutic effects:

Relief of pain and inflammation.
Slowing of the disease process in rheumatoid arthritis.

Classifications ⬆ ⬇

Therapeutic Classification: antirheumatics (DMARDs), gold compounds

Pharmacokinetics ⬆ ⬇

Absorption: 20–25% absorbed from the GI tract.

Distribution: Widely distributed; appears to concentrate in arthritic joints more than in uninvolved joints.

Metabolism/Excretion: 60% excreted by the kidneys; 40% excreted in the feces.

Half-Life: 26 days in blood; 40–128 days in tissue.

Time/Action Profile ⬆ ⬇

(anti-inflammatory activity)

ROUTE	ONSET	PEAK	DURATION
PO	3–6 mo	unknown	unknown

Patient/Family Teaching ⬆ ⬇

Instruct patient to take medication exactly as directed; do not skip or double doses. Take missed dose as soon as possible except if next dose is almost due.
Concurrent therapy with salicylates or other NSAIDs or corticosteroids is usually necessary, especially during the first few months of gold therapy. Patients should continue physical therapy and ensure adequate rest. Explain that joint damage will not be reversed; the goal is to slow or stop the disease process.
Emphasize the importance of good oral hygiene to reduce stomatitis.
Caution patient to use sunscreen and protective clothing to prevent photosensitivity reactions.
Instruct patient to report symptoms of leukopenia (fever, sore throat, signs of infection); thrombocytopenia (bleeding gums; bruising; petechiae; blood in stools, urine, or emesis); or gold toxicity immediately. Diarrhea may be resolved by ↓ the dose.
Emphasize the importance of regular visits to health care professional to monitor progress and evaluate blood and urine tests for side effects.
Rep: May cause fetal harm. Advise women of reproductive potential to notify health care professional promptly if pregnancy is planned or suspected and to avoid breastfeeding during therapy. Discuss the need for contraception while receiving this medication.

Pronunciation ⬆ ⬇

Code ⬆

NDC Code

49812- Veranova, L.P.
- 49812-0067-
  - 49812-0067-1- 1 CONTAINER in 1 CONTAINER (49812-0067-1) / 1 kg in 1 CONTAINER

54766- Sebela Pharmaceuticals Inc.
- 54766-093- RIDAURA
  - 54766-093-06- 60 CAPSULE in 1 BOTTLE (54766-093-06)

section name header

Indications ⬇

Contraind./Precautions ⬆ ⬇